ArticleBioMed research international2021
Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.
Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Postoperative radiotherapy for resected esophageal squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Development and validation of a novel pre-operative comprehensive prognostic score in esophageal squamous cell carcinoma.Bosnian journal of basic medical sciences · 2022Trial
- Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.Cancer control : journal of the Moffitt Cancer CenterTrial
- Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials.Clinical and translational radiation oncology · 2026Article
- Long-term prognostic comparison of surgery followed by adjuvant chemoradiotherapy versus definitive chemoradiotherapy in T4N0-3M0 esophageal squamous cell carcinoma: a single-center retrospective cohort study.Frontiers in oncology · 2026Article
- A pathological classification for predicting recurrence and guiding adjuvant therapy in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: a two-center cohort study.Frontiers in oncology · 2026Article
- Comparison of efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma.Journal of cardiothoracic surgery · 2025Article
- Lymph node ratio predicts adjuvant chemotherapy benefit in esophageal squamous cell carcinoma.The oncologist · 2025Article
- Identifying risk factors and evaluating therapeutic interventions for anastomotic recurrence in postoperative esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy.Frontiers in oncology · 2025Article
- Predictors of Understaging with EUS and PET-CECT in Early Esophageal Carcinoma.Journal of gastrointestinal cancer · 2024Article
- Article
- Article
- Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.Biomolecules & biomedicine · 2024Article
- Current status and prospects of diagnosis and treatment for esophageal cancer with supraclavicular lymph node metastasis.Frontiers in oncology · 2024Review
- Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node-positive esophageal squamous cell carcinoma: Is oral chemotherapy promising?Cancer medicine · 2023Article
- Clinical usefulness of the lymphocyte-to-monocyte ratio and aggregate index of systemic inflammation in patients with esophageal cancer: a retrospective cohort study.Cancer cell international · 2023Article
- Optimal Treatment Strategies for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Real-World Triple Cohort Analysis Using Propensity Score Matching.International journal of general medicine · 2023Article
- Impact of adjuvant chemotherapy for radically resected esophageal squamous cell carcinoma: a propensity score matching analysis.Frontiers in surgery · 2023Article
- Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of esophageal cancer in China. However, patient survival time after surgery remains unsatisfactory, especially in those who are pN+. This retrospective study determined the value of postoperative adjuvant therapy for patients with pN+ ESCC. From Jan 2008 to Sep 2011, 453 pN+ ESCC patients who underwent R0 resection and survived for at least 1 month were retrospectively enrolled. All patients received surgery. Some patients received surgery alone (SA,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.